中药达明饮治疗增殖期糖尿病视网膜病变的临床研究
|
摘要
目的:评价达明饮治疗增殖期糖尿病视网膜病变的有效性,探讨达明饮益气养阴,化瘀止血的作用机制。
方法:临床采集糖尿病视网膜病变增殖期眼底改变患者32例,按随机原则均等分为治疗组与对照组,治疗组口服达明饮,对照组口服二羟基苯磺酸钙(导升明)。用药前和用药1个月后分别对患者进行眼底照相、眼底荧光造影以及视力、视野、彩色多普勒超声血流成像的检查,客观评价治疗效果。
结果:
(1)治疗后治疗组总有效率为65.63%,对照组总有效率为46.88%,P<0.05治疗组优于对照组。
(2)视力:治疗组与对照组比较,进行t检验,P<0.05,两组用药前后视力均有统计学意义。
(3)眼底检查、荧光造影比较,治疗组优于对照组,治疗组总有效率为71.88%,对照组总有效率为56.67%,P<0.05两组比较有统计学意义。
(4)视野:治疗组治疗后,P<0.05,有统计学意义;对照组治疗后,P<0.05,有统计学意义;但两组比较,P>0.05,无统计学意义。
(5)两组用药后视网膜血流均有改善,治疗组治疗前后比较PSV、RI、EDV, P<0.05,均有统计学意义。对照组治疗前后比较RI ,P<0.05有统计学意义;PSV、EDV,P>0.05,差异无统计学意义。治疗组和对照组治疗后比较PSV、EDV,P<0.05,有统计学意义。RI, P>0.05,差异无统计学意义。
结论:中药达明饮治疗增殖期糖尿病视网膜病变治疗效果显著,且优于导升明。
Purposes: To evaluate the efficacy of the DA MING YIN for treatment of proliferative diabetic retinopathy(PDR),and to explore the mechanism of the DA MING YIN with functions of replenishing qi and producing yin, activating blood circulation to dissipate blood stasis.
Methods: 32 NIDDM patients with PDR and eyeground change were randomly assigned (16:16) to the treatment group (DA MING YIN) and the controlled group (DOXIUM). Examination of vision, eyeshot and Color Doppler flow imaging (CDFI); photography of eyeground, fundus fluorescein angiography before treatment and after one month were used to evaluate the effects of DA MING YIN impersonally.
Results: (1) The percentage of the total effective cases of the treatment group was 65.63%, and the controlled group was 46.88%,P<0.05,so DA MING YIN is superior to DOXIUM.
(2)Vision: Comparison in the treatment group and the controlled group has statistical significance (P<0.05) by T.The vision of two groups both have some statistical significance before treatment and after clinical therapy.
(3) The treatment group, whose percentage of the total effective cases is 71.88%, is superior to the controlled group, whose is 56.67%, in eyeground examination and fundus fluorescein angiography. Comparisons between the groups have statistical significance (P<0.05).
(4)Eyeshot: The treatment group has statistical significance (P<0.05); the controlled group has statistical significance (P>0.05); contrasts between two groups after treatment have no statistical significance (P>0.05).
(5)Retina flow of two groups both have some improvement through clinical therapy; comparisons in the treatment group have statistical significance in PSV、RI and EDV (P<0.05) before treatment and after clinical therapy. Contrasts in the controlled group' RI have statistical significance (P<0.05), but in PSV and EDV have no (P>0.05). Contrasts between two groups after treatment have statistical significance in PSV and EDV (P<0.05), but in RI have no (P>0.05).
Conclusion: Curative effect of Chinese traditional medicine DA MING YIN in proliferative diabetic retinopathy (PDR) is significant, and superior to DOXIUM.
方法:临床采集糖尿病视网膜病变增殖期眼底改变患者32例,按随机原则均等分为治疗组与对照组,治疗组口服达明饮,对照组口服二羟基苯磺酸钙(导升明)。用药前和用药1个月后分别对患者进行眼底照相、眼底荧光造影以及视力、视野、彩色多普勒超声血流成像的检查,客观评价治疗效果。
结果:
(1)治疗后治疗组总有效率为65.63%,对照组总有效率为46.88%,P<0.05治疗组优于对照组。
(2)视力:治疗组与对照组比较,进行t检验,P<0.05,两组用药前后视力均有统计学意义。
(3)眼底检查、荧光造影比较,治疗组优于对照组,治疗组总有效率为71.88%,对照组总有效率为56.67%,P<0.05两组比较有统计学意义。
(4)视野:治疗组治疗后,P<0.05,有统计学意义;对照组治疗后,P<0.05,有统计学意义;但两组比较,P>0.05,无统计学意义。
(5)两组用药后视网膜血流均有改善,治疗组治疗前后比较PSV、RI、EDV, P<0.05,均有统计学意义。对照组治疗前后比较RI ,P<0.05有统计学意义;PSV、EDV,P>0.05,差异无统计学意义。治疗组和对照组治疗后比较PSV、EDV,P<0.05,有统计学意义。RI, P>0.05,差异无统计学意义。
结论:中药达明饮治疗增殖期糖尿病视网膜病变治疗效果显著,且优于导升明。
Purposes: To evaluate the efficacy of the DA MING YIN for treatment of proliferative diabetic retinopathy(PDR),and to explore the mechanism of the DA MING YIN with functions of replenishing qi and producing yin, activating blood circulation to dissipate blood stasis.
Methods: 32 NIDDM patients with PDR and eyeground change were randomly assigned (16:16) to the treatment group (DA MING YIN) and the controlled group (DOXIUM). Examination of vision, eyeshot and Color Doppler flow imaging (CDFI); photography of eyeground, fundus fluorescein angiography before treatment and after one month were used to evaluate the effects of DA MING YIN impersonally.
Results: (1) The percentage of the total effective cases of the treatment group was 65.63%, and the controlled group was 46.88%,P<0.05,so DA MING YIN is superior to DOXIUM.
(2)Vision: Comparison in the treatment group and the controlled group has statistical significance (P<0.05) by T.The vision of two groups both have some statistical significance before treatment and after clinical therapy.
(3) The treatment group, whose percentage of the total effective cases is 71.88%, is superior to the controlled group, whose is 56.67%, in eyeground examination and fundus fluorescein angiography. Comparisons between the groups have statistical significance (P<0.05).
(4)Eyeshot: The treatment group has statistical significance (P<0.05); the controlled group has statistical significance (P>0.05); contrasts between two groups after treatment have no statistical significance (P>0.05).
(5)Retina flow of two groups both have some improvement through clinical therapy; comparisons in the treatment group have statistical significance in PSV、RI and EDV (P<0.05) before treatment and after clinical therapy. Contrasts in the controlled group' RI have statistical significance (P<0.05), but in PSV and EDV have no (P>0.05). Contrasts between two groups after treatment have statistical significance in PSV and EDV (P<0.05), but in RI have no (P>0.05).
Conclusion: Curative effect of Chinese traditional medicine DA MING YIN in proliferative diabetic retinopathy (PDR) is significant, and superior to DOXIUM.
引文
[1]董振华,等,祝堪予治疗糖尿病慢性并发症的经验,中医杂志1977;(1);12.
[2]李振中,等,糖尿病性眼底出血探讨,中西医结合眼科杂志1977;(1);10.
[3]李振中,等,糖尿病眼底出血辨治,河南中医,1998;(1);43.
[4]李振中,等,三论糖尿病性眼底出血,中医药信息1998;(1);36.
[5]李振中,尹翠梅,痰瘀互结与糖尿病血管病变[j]中华新医药,2002(1):2.
[6]刘文华,廖品正.糖尿病视网膜病变的病因及分型论治探讨[j].国医论坛,2001,16(3):15~16.
[7]邓亚萍,谢学军.滋阴补肾活血药治疗糖尿病视网膜病变的初步观察[j].中国中西医结合杂志,1992;12(5):270.
[8]冯明清.梁光宇教授治疗糖尿病学术思想简介[j].河南中医,2000,(1):15.
[9]陈通文.糖尿病论治的临床研究进展[j].中国中医药信息杂志,2000,(1):18.
[10]李劲亮.消渴明目方治疗早期糖尿病性视网膜病变35例[j].国医论坛,2000,15(6).
[11]谢学军,王明芳,糖尿病视网膜病变的病机探讨,中国中医眼科杂志,1995,5(2):86一88.
[12]朱晓林.健脾祛疲化痰法治疗糖尿病视网膜病变理论探[j]讨.中医药学刊,2005,23(7):1291～1292.
[13]孙河,郝晓楠达明饮治疗糖尿病视网膜病变的临床观察[J],中华医学会第十届全国眼科学术大会论文汇编,天津:中国天津出版社,2005,9.8-12.
[14]李志英,余杨桂,张淳,等.糖尿病视网膜病变与血瘀关系的探讨.广州中医药大学学报,1999,16(4):275～278.
[15]祁宝玉,廖岩松,应拓宽.糖尿病性视网膜病变的研究思路.中国中医眼科杂志,1998,8(1):54255.
[16]刘红娣.姚芳蔚老师治疗糖尿病性视网膜病变的经验[J].中西医结合眼科杂志,1998,16(4):233～234.
[17]郑军.中西医结合治疗增殖性糖尿病视网膜病变23例[J].江西中医药,2004,35(3):36.
[18]刘文华,廖品正.糖尿病视网膜病变的病因及分型论治探讨[J].国医论坛,2001,16(3):15～1.
[19]张宏.辨证分型治疗糖尿病性视网膜病变临床观察[J].辽宁中医杂志,2006,33(1):84.
[20]刘静.中药治疗糖尿病性视网膜病变的临床观察[J].中医杂志,1994,35(1):38.
[21]林兰.糖尿病的中西医结合论治[M ].北京:北京科学技术出版社, 2002: 300 - 304.
[22]李炳茂、李耀峰、刘慧玲,等复方大黄制剂治疗糖尿病视网膜病变200例[J] .中医杂志,2000,4(2):119.
[23]杨建华,段俊国,周春阳.糖网方治疗糖尿病视网膜病变101例[J] .河南中医,2003,23(10):37-38.
[24]葛邦颖,赵小东.中药治疗糖尿病性视网膜病变疗效观察[J].中国中医眼科杂志,1995,5(1):11-13.
[25]李振中,尹翠梅,初淑华,等.再论糖尿病性视网膜内新生血管[J].眼视光学杂志,1998,16(1):9-10.
[26]曹素兰,孙元荣,张兆岳,等.增视胶囊治疗糖尿病性视网膜病变疗效观察[J].山东中医杂志,2000,19(5):281-282.
[27]杨海燕,参归明目汤治疗气虚血瘀型糖尿病视网膜病变101例[J].新中医,1999,31(9):92.
[28]董立均,邵晓颖,中西医结合治疗糖尿病视网膜病变48例分析[J].吉林中医药,2000,(6):52.
[29]高培质,增生型糖尿病视网膜病变的中西医结合治疗[J].中国中医眼科杂志,2001,(4):196-197.
[30]吕金琢.中西医结合治疗糖尿病视网膜病变.中西医结合眼科,1989,(4):172.
[31]张西静.益气养阴、活血宁络法治疗糖尿病性视网膜病变43例[J].陕西中医,2006,27(11):1375.
[32]宗玲,张名甫,养阴益气活血法治疗糖尿病视网膜病变.吉林中医药,1995,(5):18.
[33]赵红,辨证治疗糖尿病视网膜病变[J].河南中医,2001,21(3):54.
[34]王重农,赵京伟.中医辨证施治糖尿病视网膜病变30例临床观察[J].中华实用中西医杂志,2004,17(15):2317-2318.
[35]陈鹏,贺翔鸽.丹参对糖尿病视网膜病变患者视觉功能的改善与治疗前后自由基水平变化[J].中国临床康复,2005,9(25):157-158.
[36]冯国瑞.独一味治疗糖尿病玻璃体积血[J].广西医学,2003,25(4)619-620.
[37]郑燕林,王毅,袁晓辉,等.水蛭素对增生性玻璃体视网膜病变影响的组织病理学观察[J].中国中医眼科杂志,2000,10(1):1-3 .
[38] Chung HS, Harris A, Halter PJ, et al . Regional differentes in retinal vascular reactivity [J]. Invest Ophthalmic Vis Sci, 1999, 40 (10): 2448-2453.
[39]Takagi H. Molecular mechanisms of retinal nonvascular in diabetes retinopathy[ J ]. Intern Med, 2003 (42): 2992 301.
[40] Asnaghi V, Gerhardinger C, Hoehn T, et al. A role for the polyopathway in the early neuroretinal apoptosis and glial changes induced by diabetes in the rat Diabetes2003;52(2):506-511.
[41] Obrosova IG, Minchenko AG, Vasupuram R, et al. Aldose reductase inhibitor fidarest at prevents retinal oxidative stress and vascular endothelial growth factor over expression in strep to zotoci-diabetic rats. Diabetes2003;52(3):864-871.
[42] Pfeifer MA, Schumer MP, Gelber DA [J]. Diabetes, 1997,46(suppl 2):82-89.
[43] Wautier JL, Guillausseau PJ. Advanced glycation end-products, the receptors and diabetic angiopathy. Diabete Metab,2001;27(5):535-542.
[44] Stitt AW, Li YM, Gardiner TA, et al. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature diabetic and of AGE-infused rats. Am JPathol,1997;150(2):523-531.
[45] Mamputu JC, Renier G. Advanced glycation end-products increase monocyte adhesion to retinal endothelial cells through vascular endothelial growth factor-induced ICAM-1 expression inhibitory effect of antioxidants [J]. JLeukoc Biol , 2004, 75(6)∶1062-1069.
[46] StittAW, JenkinsAJ, Cooper ME. Advanced glycation end-products and diabetic complications [J]. Exp Opin Invest Drug, 2002, 11 ( 9 )∶1205-1223 .
[47]唐仕波,李斌.应努力推动我国糖尿病视网膜病变的临床基础研究[J].中华眼底病杂志,2006,22(1):1-3.
[48] Ono Y, Umeda F, Kunisaki M, et al.[J].Diabeticologia, 1998, 41:134-140.
[49] King GL, Shiba T, Oliver J, et al. Cellular and molecular abnormalities in the Vascular endothelium of diabetes mellitus [J].Annul Rev Med, 1994, 45: 175.
[50] Lyons T, Kimura M. Effect of modified low density lip proteins on cultured capillary cells, mitigation by pre-enrichment withα-tocopherol and mechanism of toxin [J].Diabetes,1998,47(suppl 1):379.
[51]Brownlee M. Glycationand diabetic complication [J]. Diabetes, 1994, 43:836.USA 2000;97(22):12222-12226.
[52] Ozaki H, Seo MS, Ozaki K, et al. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization [J].Am J Pathol, 2000,156(2):697-707.
[53] Witmer AN, Vrensen GF, Van-Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res,2003;22(1):1-29.
[54] Matsumoto Y, Takahashi M, Ogata M. Relationship between Glycoxdiation and Cytokines in the Vitreous of eyes with diabetic Retinopathy. Jpn. [J] Ophthalmol, 2002; 46(4):406-412.
[55] Clermont AC, Alello LP, Mori F, et al. Vascular endothelial growth factor and severity of nonproliferative diabetic retinopathy mediate retinal hemodynamics in vivo: a potential role for vascular endothelial growth factor in the progression of nonproliferative diabetic retinopathy [J]. Am J Ophthalmol, 1997, 124(4):433- 446.
[56] Chan CK, Pham LN, Zhou J, et al. Differential expression of pro-and anti antigenic factors in mouse strain-dependent hypoxia- induced retinal neovascularization [J]. Lab Invest, 2005, 85(6)∶721-733.
[57]艾静,刘瑶,陈平圣,等. bFGF对兔视网膜Müller细胞表达VEGF的影响[J].眼科研究, 2007, 25(10)∶740.
[58] TatsuyaK, David V, Kiyoshi S, et a1.Knock out of insulin and IGF-1 receptorson vascular end othelial cells protects against retinal neovascularization [J]. JClin Invest, 2003, 111(12)∶1835-1842
[59] Chantelau E, Meyer-Schwickerath R. Reversion of early worsening of diabetic retinopathy by deliberate restoration of poor metabolic control[J]. Ophthalmologic, 2003, 217(5)∶373-377.
[60] Lauszus FF, Klebe JG, Bek T, et a1. Increased serum IGF-I during pregnancy is associated with progression of diabetic retinopathy [J].Diabetes, 2003, 52(3)∶852-856.
[61] Smith LE, Shen W, Perruzzi C, et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 1999; 5:1390-5.
[62] Smith LEH, Kopchick JJ, Chen W, et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 1997, 276:1706-9.
[63]Dawson DW, Volpert OV, Gillisp, et al, Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science, 1999, 285,245.
[64]侯承花,刘成玉.糖尿病视网膜病变与红细胞变形能力和膜磷脂及收缩蛋白变化的关系[J].中华眼底病杂志,1999,15(3):160-162.
[65] Rand LI, Krolewski AS, Aiello LM, et al. Multiple factors in the prediction of risk of proliferative diabetic retinopathy [J]. N Engl J Med, 1985, 313(23):1433-1438.
[66]刘卫,张勇进.糖尿病性视网膜病2002年悉尼举行的国际眼科学会议变[J].国外医学眼科学分册,2005,29(5):352-357.
[67] Rema M, Saravanan G, Deepa R, et al. Familial clustering of diabetic retinopathy in South Indian type2-diabetic patients [J]. Diabetes Med, 2002, 19(11):910-916.
[68] Warpeha KM, Chakravarehy U. Molecular genetics of microvascular disease in diabetic retinopathy [J].Eye, 2003, 17(3):305-311.
[69] The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of log-term complications in insulin-dependent diabetes mellitus. N Engl [J] Med 1993;329:977-86.
[70]刘家琦,李风鸣.实用眼科学[M].第2版.北京:人民出版社,1994.481.
[71]黄红深.增殖性糖尿病视网膜病变的治疗[J].临床眼科杂志, 2002, 10 (2) : 146 - 147 .
[72]黎晓新,王景昭.玻璃体视网膜手术学[M].北京:人民卫生出版社,2000.295-298.
[73] Infeld DA, O Shea J G .Diabetic retinopathy[J] .Postgrad Med [J], 1998, 74: 129- 133.
[74] Cunha Vaz J .Lowering the risk of visual impairment and blindness [J] . Diabetes Med, 1998, 15 (Supp14): 47 - 50.
[75] Fong DS, Ferris FL, Davis MD. Causes of severe visual loss in the early treatment diabetic retinopathy study: ET2DRS report No. 24 Early Treatment Diabetic Retinopathy Study research group [J]. Am Ophthalmol, 1999, 127(2): 137- 141.
[76]王冰,陈平,翁景宁.增殖性糖尿病视网膜病变玻璃体手术并发症分析[ J ].国际眼科杂志, 2008, 8 (6) : 1259- 1261.
[77]孙河,滕晓明,李雪莹,等.糖尿病视网膜病变的研究概况[J].中医药信息,2004(4):25.
[78]朱益华,龚腾升,李含玉.正常人眼动脉及视网膜中央动脉血流参数测定.昆明医学院学报,1999,20(4):40-41.
[79]杨焰.应用彩色多普勒检测糖尿病视网膜病变血流动力学的意义.[J].广州医药,2000,31:59-60.
[80]王先银,廖明松,王普杰,等.彩色多普勒评价早期糖尿病视网膜病变血流变化,[J].中国临床康复,2006,10:97,100.
[81]聂芳,童明辉,车岩.糖尿病眼底动脉血流动力学的彩色多普勒超声研究.[J].医学影像学杂志2005年第15卷第11期,927-929.
[82]乔丽华,耿美玲.2糖尿病视网膜病变的彩色多普勒观察分析.[J].眼科研究,1999,17(6):437.
[83]苗青,中药达明饮治疗非增殖期糖尿病视网膜病变的临床实验研究.黑龙江中医药大学硕士论文. 2009.5.
[2]李振中,等,糖尿病性眼底出血探讨,中西医结合眼科杂志1977;(1);10.
[3]李振中,等,糖尿病眼底出血辨治,河南中医,1998;(1);43.
[4]李振中,等,三论糖尿病性眼底出血,中医药信息1998;(1);36.
[5]李振中,尹翠梅,痰瘀互结与糖尿病血管病变[j]中华新医药,2002(1):2.
[6]刘文华,廖品正.糖尿病视网膜病变的病因及分型论治探讨[j].国医论坛,2001,16(3):15~16.
[7]邓亚萍,谢学军.滋阴补肾活血药治疗糖尿病视网膜病变的初步观察[j].中国中西医结合杂志,1992;12(5):270.
[8]冯明清.梁光宇教授治疗糖尿病学术思想简介[j].河南中医,2000,(1):15.
[9]陈通文.糖尿病论治的临床研究进展[j].中国中医药信息杂志,2000,(1):18.
[10]李劲亮.消渴明目方治疗早期糖尿病性视网膜病变35例[j].国医论坛,2000,15(6).
[11]谢学军,王明芳,糖尿病视网膜病变的病机探讨,中国中医眼科杂志,1995,5(2):86一88.
[12]朱晓林.健脾祛疲化痰法治疗糖尿病视网膜病变理论探[j]讨.中医药学刊,2005,23(7):1291～1292.
[13]孙河,郝晓楠达明饮治疗糖尿病视网膜病变的临床观察[J],中华医学会第十届全国眼科学术大会论文汇编,天津:中国天津出版社,2005,9.8-12.
[14]李志英,余杨桂,张淳,等.糖尿病视网膜病变与血瘀关系的探讨.广州中医药大学学报,1999,16(4):275～278.
[15]祁宝玉,廖岩松,应拓宽.糖尿病性视网膜病变的研究思路.中国中医眼科杂志,1998,8(1):54255.
[16]刘红娣.姚芳蔚老师治疗糖尿病性视网膜病变的经验[J].中西医结合眼科杂志,1998,16(4):233～234.
[17]郑军.中西医结合治疗增殖性糖尿病视网膜病变23例[J].江西中医药,2004,35(3):36.
[18]刘文华,廖品正.糖尿病视网膜病变的病因及分型论治探讨[J].国医论坛,2001,16(3):15～1.
[19]张宏.辨证分型治疗糖尿病性视网膜病变临床观察[J].辽宁中医杂志,2006,33(1):84.
[20]刘静.中药治疗糖尿病性视网膜病变的临床观察[J].中医杂志,1994,35(1):38.
[21]林兰.糖尿病的中西医结合论治[M ].北京:北京科学技术出版社, 2002: 300 - 304.
[22]李炳茂、李耀峰、刘慧玲,等复方大黄制剂治疗糖尿病视网膜病变200例[J] .中医杂志,2000,4(2):119.
[23]杨建华,段俊国,周春阳.糖网方治疗糖尿病视网膜病变101例[J] .河南中医,2003,23(10):37-38.
[24]葛邦颖,赵小东.中药治疗糖尿病性视网膜病变疗效观察[J].中国中医眼科杂志,1995,5(1):11-13.
[25]李振中,尹翠梅,初淑华,等.再论糖尿病性视网膜内新生血管[J].眼视光学杂志,1998,16(1):9-10.
[26]曹素兰,孙元荣,张兆岳,等.增视胶囊治疗糖尿病性视网膜病变疗效观察[J].山东中医杂志,2000,19(5):281-282.
[27]杨海燕,参归明目汤治疗气虚血瘀型糖尿病视网膜病变101例[J].新中医,1999,31(9):92.
[28]董立均,邵晓颖,中西医结合治疗糖尿病视网膜病变48例分析[J].吉林中医药,2000,(6):52.
[29]高培质,增生型糖尿病视网膜病变的中西医结合治疗[J].中国中医眼科杂志,2001,(4):196-197.
[30]吕金琢.中西医结合治疗糖尿病视网膜病变.中西医结合眼科,1989,(4):172.
[31]张西静.益气养阴、活血宁络法治疗糖尿病性视网膜病变43例[J].陕西中医,2006,27(11):1375.
[32]宗玲,张名甫,养阴益气活血法治疗糖尿病视网膜病变.吉林中医药,1995,(5):18.
[33]赵红,辨证治疗糖尿病视网膜病变[J].河南中医,2001,21(3):54.
[34]王重农,赵京伟.中医辨证施治糖尿病视网膜病变30例临床观察[J].中华实用中西医杂志,2004,17(15):2317-2318.
[35]陈鹏,贺翔鸽.丹参对糖尿病视网膜病变患者视觉功能的改善与治疗前后自由基水平变化[J].中国临床康复,2005,9(25):157-158.
[36]冯国瑞.独一味治疗糖尿病玻璃体积血[J].广西医学,2003,25(4)619-620.
[37]郑燕林,王毅,袁晓辉,等.水蛭素对增生性玻璃体视网膜病变影响的组织病理学观察[J].中国中医眼科杂志,2000,10(1):1-3 .
[38] Chung HS, Harris A, Halter PJ, et al . Regional differentes in retinal vascular reactivity [J]. Invest Ophthalmic Vis Sci, 1999, 40 (10): 2448-2453.
[39]Takagi H. Molecular mechanisms of retinal nonvascular in diabetes retinopathy[ J ]. Intern Med, 2003 (42): 2992 301.
[40] Asnaghi V, Gerhardinger C, Hoehn T, et al. A role for the polyopathway in the early neuroretinal apoptosis and glial changes induced by diabetes in the rat Diabetes2003;52(2):506-511.
[41] Obrosova IG, Minchenko AG, Vasupuram R, et al. Aldose reductase inhibitor fidarest at prevents retinal oxidative stress and vascular endothelial growth factor over expression in strep to zotoci-diabetic rats. Diabetes2003;52(3):864-871.
[42] Pfeifer MA, Schumer MP, Gelber DA [J]. Diabetes, 1997,46(suppl 2):82-89.
[43] Wautier JL, Guillausseau PJ. Advanced glycation end-products, the receptors and diabetic angiopathy. Diabete Metab,2001;27(5):535-542.
[44] Stitt AW, Li YM, Gardiner TA, et al. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature diabetic and of AGE-infused rats. Am JPathol,1997;150(2):523-531.
[45] Mamputu JC, Renier G. Advanced glycation end-products increase monocyte adhesion to retinal endothelial cells through vascular endothelial growth factor-induced ICAM-1 expression inhibitory effect of antioxidants [J]. JLeukoc Biol , 2004, 75(6)∶1062-1069.
[46] StittAW, JenkinsAJ, Cooper ME. Advanced glycation end-products and diabetic complications [J]. Exp Opin Invest Drug, 2002, 11 ( 9 )∶1205-1223 .
[47]唐仕波,李斌.应努力推动我国糖尿病视网膜病变的临床基础研究[J].中华眼底病杂志,2006,22(1):1-3.
[48] Ono Y, Umeda F, Kunisaki M, et al.[J].Diabeticologia, 1998, 41:134-140.
[49] King GL, Shiba T, Oliver J, et al. Cellular and molecular abnormalities in the Vascular endothelium of diabetes mellitus [J].Annul Rev Med, 1994, 45: 175.
[50] Lyons T, Kimura M. Effect of modified low density lip proteins on cultured capillary cells, mitigation by pre-enrichment withα-tocopherol and mechanism of toxin [J].Diabetes,1998,47(suppl 1):379.
[51]Brownlee M. Glycationand diabetic complication [J]. Diabetes, 1994, 43:836.USA 2000;97(22):12222-12226.
[52] Ozaki H, Seo MS, Ozaki K, et al. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization [J].Am J Pathol, 2000,156(2):697-707.
[53] Witmer AN, Vrensen GF, Van-Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res,2003;22(1):1-29.
[54] Matsumoto Y, Takahashi M, Ogata M. Relationship between Glycoxdiation and Cytokines in the Vitreous of eyes with diabetic Retinopathy. Jpn. [J] Ophthalmol, 2002; 46(4):406-412.
[55] Clermont AC, Alello LP, Mori F, et al. Vascular endothelial growth factor and severity of nonproliferative diabetic retinopathy mediate retinal hemodynamics in vivo: a potential role for vascular endothelial growth factor in the progression of nonproliferative diabetic retinopathy [J]. Am J Ophthalmol, 1997, 124(4):433- 446.
[56] Chan CK, Pham LN, Zhou J, et al. Differential expression of pro-and anti antigenic factors in mouse strain-dependent hypoxia- induced retinal neovascularization [J]. Lab Invest, 2005, 85(6)∶721-733.
[57]艾静,刘瑶,陈平圣,等. bFGF对兔视网膜Müller细胞表达VEGF的影响[J].眼科研究, 2007, 25(10)∶740.
[58] TatsuyaK, David V, Kiyoshi S, et a1.Knock out of insulin and IGF-1 receptorson vascular end othelial cells protects against retinal neovascularization [J]. JClin Invest, 2003, 111(12)∶1835-1842
[59] Chantelau E, Meyer-Schwickerath R. Reversion of early worsening of diabetic retinopathy by deliberate restoration of poor metabolic control[J]. Ophthalmologic, 2003, 217(5)∶373-377.
[60] Lauszus FF, Klebe JG, Bek T, et a1. Increased serum IGF-I during pregnancy is associated with progression of diabetic retinopathy [J].Diabetes, 2003, 52(3)∶852-856.
[61] Smith LE, Shen W, Perruzzi C, et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 1999; 5:1390-5.
[62] Smith LEH, Kopchick JJ, Chen W, et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 1997, 276:1706-9.
[63]Dawson DW, Volpert OV, Gillisp, et al, Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science, 1999, 285,245.
[64]侯承花,刘成玉.糖尿病视网膜病变与红细胞变形能力和膜磷脂及收缩蛋白变化的关系[J].中华眼底病杂志,1999,15(3):160-162.
[65] Rand LI, Krolewski AS, Aiello LM, et al. Multiple factors in the prediction of risk of proliferative diabetic retinopathy [J]. N Engl J Med, 1985, 313(23):1433-1438.
[66]刘卫,张勇进.糖尿病性视网膜病2002年悉尼举行的国际眼科学会议变[J].国外医学眼科学分册,2005,29(5):352-357.
[67] Rema M, Saravanan G, Deepa R, et al. Familial clustering of diabetic retinopathy in South Indian type2-diabetic patients [J]. Diabetes Med, 2002, 19(11):910-916.
[68] Warpeha KM, Chakravarehy U. Molecular genetics of microvascular disease in diabetic retinopathy [J].Eye, 2003, 17(3):305-311.
[69] The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of log-term complications in insulin-dependent diabetes mellitus. N Engl [J] Med 1993;329:977-86.
[70]刘家琦,李风鸣.实用眼科学[M].第2版.北京:人民出版社,1994.481.
[71]黄红深.增殖性糖尿病视网膜病变的治疗[J].临床眼科杂志, 2002, 10 (2) : 146 - 147 .
[72]黎晓新,王景昭.玻璃体视网膜手术学[M].北京:人民卫生出版社,2000.295-298.
[73] Infeld DA, O Shea J G .Diabetic retinopathy[J] .Postgrad Med [J], 1998, 74: 129- 133.
[74] Cunha Vaz J .Lowering the risk of visual impairment and blindness [J] . Diabetes Med, 1998, 15 (Supp14): 47 - 50.
[75] Fong DS, Ferris FL, Davis MD. Causes of severe visual loss in the early treatment diabetic retinopathy study: ET2DRS report No. 24 Early Treatment Diabetic Retinopathy Study research group [J]. Am Ophthalmol, 1999, 127(2): 137- 141.
[76]王冰,陈平,翁景宁.增殖性糖尿病视网膜病变玻璃体手术并发症分析[ J ].国际眼科杂志, 2008, 8 (6) : 1259- 1261.
[77]孙河,滕晓明,李雪莹,等.糖尿病视网膜病变的研究概况[J].中医药信息,2004(4):25.
[78]朱益华,龚腾升,李含玉.正常人眼动脉及视网膜中央动脉血流参数测定.昆明医学院学报,1999,20(4):40-41.
[79]杨焰.应用彩色多普勒检测糖尿病视网膜病变血流动力学的意义.[J].广州医药,2000,31:59-60.
[80]王先银,廖明松,王普杰,等.彩色多普勒评价早期糖尿病视网膜病变血流变化,[J].中国临床康复,2006,10:97,100.
[81]聂芳,童明辉,车岩.糖尿病眼底动脉血流动力学的彩色多普勒超声研究.[J].医学影像学杂志2005年第15卷第11期,927-929.
[82]乔丽华,耿美玲.2糖尿病视网膜病变的彩色多普勒观察分析.[J].眼科研究,1999,17(6):437.
[83]苗青,中药达明饮治疗非增殖期糖尿病视网膜病变的临床实验研究.黑龙江中医药大学硕士论文. 2009.5.